LXRX earnings call for the period ending March 31, 2019.
News & Analysis: Lexicon Pharmaceuticals
American regulators rejected a type 1 diabetes treatment that analysts predicted would eventually eclipse $450 million in annual revenue.
Poor prospects and a big disappointment hit these stocks.
LXRX earnings call for the period ending December 31, 2018.
European experts don't have the same concerns over the company's lead drug as their American peers, recommending it for patients with type 1 diabetes.
Innovative insulin pumps and promising drugs make these three companies worthy of investors' attention.
The company's lead drug candidate got thrown into a whirlwind of uncertainty.
Wall Street’s slot machines don’t need to be employed to make big returns.
An advisory committee arrived at an impasse on the risk profile of one of the company's drug candidates.
Find out why our healthcare contributors believe that these biotechs are great buys right now.